Shots:
- SpinaFX has received MDR CE Mark for its Triojection System, which delivers a controlled ozone-oxygen gas mixture for procedures. Triojection also received US FDA’ IDE approval in Jun 2026
- SpinaFX is engaging distribution partners to launch Triojection in priority markets, initially targeting pts with persistent pain from contained herniated discs who have failed conservative therapy & may not be ideal candidates for surgery
- Triojection is an image-guided, minimally invasive device that combines real-time imaging with in-syringe ozone concentration measurement to enable reproducible intradiscal procedures in ambulatory & hospital settings, with potential to reduce the need for surgery
Ref: PRnewswire | Image: ElectroWire Medical | Press Release
R
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
